Quantitative in silico analysis of SARS-CoV-2 S-RBD omicron mutant transmissibility

被引:17
|
作者
Hanai, Toshihiko [1 ]
机构
[1] Res Inst Prod Dev 4F, Hlth Res Fdn, Sakyo Ku, Kyoto 6060805, Japan
关键词
SARS-CoV-2 omicron valiant; ACE-2; Binding affinity; Quantitative in silico analysis; Molecular interaction energy; Docking inhibitor;
D O I
10.1016/j.talanta.2022.123206
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Covid-19 variants transmissibility was quantitatively analyzed in silico to understand the reaction mechanisms and to find the reaction inhibitors. Especially, SARS-CoV-2 omicron mutant (omicron S-RBD) binding affinity with human angiotensin-converting enzyme-2 (ACE-2) was quantitatively analyzed using molecular interaction (MI) energy values (kcal.mol- 1) between the S-RBD and ACE-2. The MI of their optimized complex structures demonstrated that omicron's MI value (749.8) was 1.4 times delta MI (538.1) and 2.7 times alfa MI (276.9). The omicron S-RBD demonstrated the most vital transmissible strength. The 14 currently proposed medical treatment compounds did not show as the inhibitors to block the omicron S-RBD and ACE-2 binding; instead, they adsorbed at the ACE-2 active site and may inhibit the ACE-2 activity. A modified candidate (Gallo catechin gallate) whose two phenolic hydroxy groups were replaced with two carboxy groups was repulsed from ACE-2, indicating that further modification of medical treatment candidates may produce an effective docking inhibitor.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] In silico SARS-CoV-2 vaccine development for Omicron strain using reverse vaccinology
    Li, Vladimir
    Lee, Chul
    Yoo, DongAhn
    Cho, Seoae
    Kim, Heebal
    GENES & GENOMICS, 2022, 44 (8) : 937 - 944
  • [32] In silico design of miniprotein to inhibit SARS-CoV-2 variant Omicron spike protein
    Wu, Jianhua
    Zhang, Hong-Xing
    Zhang, Jilong
    PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 2023, 25 (21) : 14711 - 14725
  • [33] Two rapid SARS-CoV-2 disposable devices for semi-quantitative S-RBD antibody levels determination compared with CLIA and ELISA assays at different protective thresholds
    Padoan, Andrea
    Cosma, Chiara
    Galla, Luisa
    Basso, Daniela
    Plebani, Mario
    CLINICA CHIMICA ACTA, 2022, 529 : 104 - 108
  • [34] In silico SARS-CoV-2 vaccine development for Omicron strain using reverse vaccinology
    Vladimir Li
    Chul Lee
    DongAhn Yoo
    Seoae Cho
    Heebal Kim
    Genes & Genomics, 2022, 44 : 937 - 944
  • [35] Interactions between heparin and SARS-CoV-2 spike glycoprotein RBD from omicron and other variants
    Gelbach, Adrianne L. L.
    Zhang, Fuming
    Kwon, Seok-Joon
    Bates, John T. T.
    Farmer, Andrew P. P.
    Dordick, Jonathan S. S.
    Wang, Chunyu
    Linhardt, Robert J. J.
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [36] Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD
    Li, Qianqian
    Zhang, Mengyi
    Liang, Ziteng
    Zhang, Li
    Wu, Xi
    Yang, Chaoying
    An, Yimeng
    Tong, Jincheng
    Liu, Shuo
    Li, Tao
    Cui, Qianqian
    Nie, Jianhui
    Wu, Jiajing
    Huang, Weijin
    Wang, Youchun
    MEDCOMM, 2022, 3 (02):
  • [37] Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions
    Liu, Xiaofeng
    Jiang, Luying
    Li, Li
    Lu, Fuping
    Liu, Fufeng
    HELIYON, 2023, 9 (01)
  • [38] Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
    Uriu, Keiya
    Ito, Jumpei
    Zahradnik, Jiri
    Fujita, Shigeru
    Kosugi, Yusuke
    Schreiber, Gideon
    Sato, Kei
    LANCET INFECTIOUS DISEASES, 2023, 23 (03): : 280 - 281
  • [39] Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection
    Tomassetti, Flaminia
    Nuccetelli, Marzia
    Sarubbi, Serena
    Gisone, Francesca
    Ciotti, Marco
    Spinazzola, Francesco
    Ricotta, Cristina
    Cagnoli, Monica
    Borgatti, Monica
    Iannetta, Marco
    Andreoni, Massimo
    Calugi, Graziella
    Pieri, Massimo
    Bernardini, Sergio
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 99
  • [40] Omicron SARS-CoV-2 variant of concern A review on its transmissibility, immune evasion, reinfection, and severity
    Mohsin, Md
    Mahmud, Sultan
    MEDICINE, 2022, 101 (19) : E29165